Intellectus Partners LLC trimmed its holdings in GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) by 18.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 50,720 shares of the biotechnology company’s stock after selling 11,255 shares during the period. Intellectus Partners LLC’s holdings in GlycoMimetics were worth $120,000 as of its most recent filing with the Securities & Exchange Commission.
Separately, MJP Associates Inc. ADV acquired a new position in GlycoMimetics in the 4th quarter valued at about $238,000. Institutional investors own 75.19% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have recently commented on GLYC. StockNews.com downgraded GlycoMimetics from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of GlycoMimetics in a report on Wednesday, March 27th. Finally, Capital One Financial reissued an “overweight” rating on shares of GlycoMimetics in a report on Thursday, February 22nd.
GlycoMimetics Stock Down 5.5 %
Shares of GLYC opened at $1.55 on Tuesday. GlycoMimetics, Inc. has a 12 month low of $1.11 and a 12 month high of $3.53. The firm’s 50 day moving average is $2.63 and its 200-day moving average is $2.34.
GlycoMimetics (NASDAQ:GLYC – Get Free Report) last posted its quarterly earnings results on Wednesday, March 27th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The company had revenue of $0.01 million during the quarter. As a group, research analysts anticipate that GlycoMimetics, Inc. will post -0.54 earnings per share for the current fiscal year.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.
See Also
- Five stocks we like better than GlycoMimetics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Trend-Following Entries for Income Investors
- How to Invest in Small Cap Stocks
- 3 Stocks Mega Investors Are Buying
- What Investors Need to Know About Upcoming IPOs
- Can Disney Stock Triple Before 2030?
Want to see what other hedge funds are holding GLYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report).
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
